Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

Bone Marrow Transplantation volume 33, pages 131–132 (2004)Cite this article

Established acute graft-versus-host disease (aGVHD) is commonly treated with cytotoxic agents or glucocorticoids,1,2 since studies using antithymocyte globulin (ATG) demonstrated no improvement over cyclosporine (CSP) or methylprednisolone (MP). In addition, ATG was associated with poor survival.3 Alemtuzumab targets the CD52 antigen and is effective in the prevention of aGVHD;4,5 however, no data have been reported on the use of this drug for the treatment of pre-existing aGVHD.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Oblon DJ, Felker D, Coyle K et al. High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation. Bone Marrow Transplant 1992; 10: 355–357.

    CAS  Google Scholar 

  2. Gaziev D, Polchi P, Galimberti M et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997; 63: 854–860.

    Article  CAS  Google Scholar 

  3. Arai S, Margolis J, Zahurak M et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.

    Article  Google Scholar 

  4. Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76.

    Article  CAS  Google Scholar 

  5. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  CAS  Google Scholar 

  6. Buggins AS, Mufti GJ, Fishlock K et al. Peripheral blood dendritic cells express CD52 and are depleted in vivo by treatment with Campath-1H. Blood 2001; 98: 2048 (abstract 1543).

    Google Scholar 

  7. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Haematology, Division of Haematology, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini, 71013, San Giovanni Rotondo (FG), Italy

    A M Carella, G Beltrami, P R Scalzulli, A M Carella Jr & M T Corsetti

Authors
  1. A M Carella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Beltrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P R Scalzulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A M Carella Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M T Corsetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carella, A., Beltrami, G., Scalzulli, P. et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 33, 131–132 (2004). https://doi.org/10.1038/sj.bmt.1704322

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704322

This article is cited by

Search

Advanced search

Quick links